AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04846803 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABU bladder lavage
Description: Clinical effect of preventive treatment (prophylactic treatment) - bladder lavage with the non-pathogenic bacterial strain (ABU)
Study NCT04846803 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline bladder lavage
Description: Clinical effect of preventive treatment (prophylactic treatment) - bladder lavage with saline
Study NCT06490679 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hand and ultrasonic scalers and curettes
Description: Combination of ultrasonic and hand instrumentation only. Pockets ≥7 mm will be subgingivally debrided using the piezo device according to manufacturer's instructions, and hand curettes will be used until the operator considers the surfaces to be sufficiently clean and free of deposits.
Study NCT06490679 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electro Medical Systems AIRFLOW® Prophylaxis Master Device
Description: (a) Disclosure of biofilm with erythrosine, (b) Removal of supragingival and subgingival (up to 10 mm) biofilm and stains with the use of AIRFLOW® Master Piezon® with AIRFLOW® PLUS powder (EMS-Dental, Nyon Switzerland).~(c) Supra- and sub-gingival debridement by using the AIRFLOW® Master Piezon® device with Piezon NO PAIN® (EMS-Dental) technology.
Study NCT04668235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZVUDINE
Description: 5 tablets QD + standard treatment for up to 14 days
Study NCT05298332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-2173 50 mg
Description: ATI-2173 is a phosphoramidate prodrug of the oral, non-chain terminating nucleoside analog clevudine being developed by Antios Therapeutics, Inc. for treatment of men and women with chronic hepatitis B (CHB)
Study NCT05492331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Patient preferred artist or music genre to be playing from an iPad
Study NCT05914688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3209590 (Formulation 1)
Description: Administered SC.
Study NCT04668235 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZVUDINE placebo
Description: 5 tablets QD + standard treatment for up to 14 days
Study NCT05039008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction
Description: The intervention protocol will be carried out under the same environmental conditions and, as far as possible, at the same time. The intervention will last 4 weeks, with a periodicity of 3 weekly sessions. In total there will be 12 sessions that will last between 15 and 30 minutes depending on the number of joints affected.
Study NCT05914688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3209590 (Formulation 2)
Description: Administered SC.
Study NCT05835609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM534
Description: PM534 drug product is provided as a powder for concentrate for solution for infusion, is a sterile, preservative-free, lyophilized white cake in a single-dose vial for reconstitution prior to intravenous infusion.
Study NCT04923087 — intervention group
Intervention type: DEVICE
Intervention: Compare the noise and pleasure of crunching between two hyperprotein nutritional supplements
Description: Validate the evaluation criteria Do you hear the biscuit crunch? and Is it a pleasure?
Study NCT06399588 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention for Adolescent Tobacco Initiation Prevention (IATIP)
Description: The IATIP is an evidence-based tobacco prevention program tailored for Bangladeshi adolescents, integrating Behavior Change Techniques, the Behavior Change Wheel, and the Theoretical Domains Framework. Utilizing the Arena Blended Connected (ABC) model ensures effective delivery. Six key learning types are integrated to optimize knowledge acquisition, concept exploration, collaboration, discussions, practical application, and skill development. The curriculum comprises three core components addressing adolescents' challenges: the information curriculum cultivates factual awareness, the social competence curriculum strengthens refusal skills and social competencies, and the social influence curriculum builds resilience against tobacco-promoting social influences.
Study NCT06216314 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heart rate (HR)
Description: Runners ran according to speeds and HR associated with ventilatory thresholds. Z1, zone 1: intensity zone below the first ventilatory threshold; Z2: zone 2, intensity zone between the first and second ventilatory threshold; Z3: zone 3, intensity zone above the second ventilatory threshold.
Study NCT06216314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Race pace based approach (RP)
Description: Runners ran respecting three intensity zones.~The average speed achieved in the 7-km was calculated. From this, three intensity zones were calculated, adhering to the % of the race pace of the 7-km test.~Z1 corresponds to less than 80% of race pace, Z2 is between 80-95%, and Z3 corresponds to over 95% of race pace
Study NCT06216314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart rate + heart rate variability (HRV)
Description: Runners completed training sessions based on HR values and velocities associated with ventilatory thresholds (i.e., Z1, zone 1: intensity zone below the first ventilatory threshold; Z2: zone 2, intensity zone between the first and second ventilatory threshold; Z3: zone 3, intensity zone above the second ventilatory threshold. The training sessions were based on physiological thresholds and daily HRV cues. High-intensity training was performed only under optimal HRV conditions, thus only when each participant had HRV values in their reference range. If HRV was not optimal, low-intensity training was prescribed. If HRV was not optimal for two days consecutively, rest was prescribed.
Study NCT04682990 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tor Vergata Electronic Nose (TV eNose)
Description: Participants will be asked to perform a breath sampling with a nose clamp in Alveolar sampling bag. This exhaled breath in the sampling bag will be analyse with the TV eNose
Study NCT04682990 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tor Vergata Electronic Nose (TV eNose)
Description: Participants will be asked to perform a breath sampling with a nose clamp in Alveolar sampling bag. This exhaled breath in the sampling bag will be analyse with the TV eNose
Study NCT04682990 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey & Physical Exam
Description: Perform a oriented survey for risk factors, symptoms and a complete physical exam.
Study NCT05608473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posture Exercises
Description: A 10-minute video consisted of 14 cervical and thoracal postural exercises was uploaded to the computers of the participants. Participants were asked to do these exercises simultaneously with the video, 3 days in a week for 6 weeks. During theese weeks, the participants were checked by sms and they were asked to keep an exercise diary. For progression, the number of repetitions was increased in the 3rd week and the number of sets in the 5th week.
Study NCT04813783 — intervention group
Intervention type: OTHER
Intervention: Mucositis care training to be given in line with MASCC / ISOO 2019
Description: Mucositis care training to be given in line with MASCC / ISOO 2019
Study NCT06361121 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mid-point transverse process to pleura (MTP) block
Description: the T1-T12 thoracic spinal levels will be sonographically identified using a high frequency linear US probe (HFL_50, 15_6MHz). Then the probe will be placed vertically and nearly 3 cm lateral to the spinous process at the thoracic level T4/T5. The paraspinal muscles (erector spinae, trapezius, rhomboid), transverse processes , superior costo-transverse ligament (SCTL) and parietal pleura will be all identified under parasagittal scanning.~In MTP block group, A 22G, 50mm block needle (SONOTAP,Pajunk, -Geisingen,Germany) will be inserted in the cranial to caudal direction via an in-plane approach between the 2 transverse processes and advanced till it reaches the mid-point between the transverse process and pleura. After negative aspiration of blood or air, a total volume of 20 ml of bupivacaine 0.25% ( not exceeding a maximum dose of 2 mg/kg) will be injected superficial to the SCTL.
Study NCT06361121 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Paravertebral Block
Description: In the TPV block group , the transverse process and the pleura will be identified and the needle will be inserted in the cranial to caudal direction till it pierces the SCTL and reaches the paravertebral space. After negative aspiration of blood or air a total volume of 20 ml of bupivacaine 0.25% will be injected displacing the pleura downwards
Study NCT05141617 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic treatment
Description: Patients in the endoscopic treatment receive endoscopic variceal ligation and N-butyl-cyanoacrylate according to the type of varices
Study NCT05141617 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TIPS
Description: Patients in the TIPS group receive Transjugular Intrahepatic Portosystemic Shunt
Study NCT04682990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey & Physical Exam
Description: Perform a oriented survey for risk factors, symptoms and a complete physical exam.
Study NCT04682990 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: TB LAMP test
Description: Collection of Sputum samples and Perform TB-LAMP (temperature-independent way of amplifying DNA from TB organisms)
Study NCT04682990 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TB LAMP test
Description: Collection of Sputum samples and Perform TB-LAMP (temperature-independent way of amplifying DNA from TB organisms)
Study NCT04682990 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sputum Samples
Description: Sputum samples for Ziehl Neelsen smear or Culture in L-J (if required by the medical staff)
Study NCT04682990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sputum Samples
Description: Sputum samples for Ziehl Neelsen smear or Culture in L-J (if required by the medical staff)
Study NCT04682990 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chest X-Ray
Description: Perform anteroposterior chest X-ray (if required by the medical staff)
Study NCT04682990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest X-Ray
Description: Perform anteroposterior chest X-ray (if required by the medical staff)
Study NCT04682990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow Up 5 days after beginning of Tx.
Description: Following the usual planning of the center for Positive TB Patients, they will be asked to come 5 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, to determine progress of treatment.
Study NCT04682990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow Up & 15 days after beginning of Tx.
Description: Following the usual planning of the center for Positive TB Patients, they will be asked to come during treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, to determine progress of treatment.
Study NCT04682990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow Up & 30 days after beginning of Tx.
Description: Following the usual planning of the center for Positive TB Patients, they will be asked to come during treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, to determine progress of treatment.
Study NCT05003661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents' Voice
Description: the intervention is recording of parents voice of reading children's book.
Study NCT05430230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen 500 Mg
Description: naproxen tablets
Study NCT05788705 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: apigenin and glycyrrhizin
Description: apigenin will be administered as capsule (10mg,eq 200mg Matricaria chamomilla L extract) two times daily. Also, glycyrrhizin  will be administered as capsule(50 mg eq 250 mg licorice extract) two times daily. The two types of capsules administration will be continue for 6 months
Study NCT05788705 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: glycyrrhizin and boswellic acid
Description: boswellic acid will be administered as capsule (200mg,eq 250mg Boswellia serrata extract) two times daily. Also, glycyrrhizin  will be administered as capsule(50 mg eq 250 mg licorice extract) two times daily. The two types of capsules administration will be continue for 6 months
Study NCT05788705 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo capsule will be administered two times daily for 6 months
Study NCT05430230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: lactose NF
Study NCT05381194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPaL(M) regimen
Description: Patients diagnosed with MDR/RR-TB are initially assigned to the BPaLM regimen as a single-arm for treatment initiation. Afterward, if MDR/RR-TB is confirmed to be fluoroquinolone-resistant by molecular or phenotypic DST, the treatment is switched to the BPaL regimen (for 24 weeks). On the other hand, if MDR/RR-TB is confirmed to be fluoroquinolone-susceptible, treatment for MDR/RR-TB is maintained with the BPaLM regimen (for 26 weeks).~The dosage of each medication is as follows:~* Bedaquiline 400mg/day for the 2 weeks, 200mg/TIW afterward~* Pretomanid 200mg/day~* Linezolid 600mg/day for the 9weeks, 300mg/day afterward~* Moxifloxacin 400mg/day
Study NCT04994990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA Standard Dose
Description: Active comparator group will be treated for full upper face wrinkles with standard recommended doing of onabotulinumtoxinA
Study NCT04994990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA Half Standard Dose
Description: Experimental group will be treated for full upper face wrinkles with half of the standard recommended doing of onabotulinumtoxinA
Study NCT06363006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI+Cardunilimab
Description: Cardonilizumab 6mg/kg, IV, Q2W + lenvatinib 8mg (body weight \< 60kg) or 12mg(body weight ≥60kg) PO, QD, / Sorafenib 400mg, PO, BID/ Regorafenib 160mg, PO, QD/ Donafenib 200mg, PO, BID。 omniscience
Study NCT05127889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: curodont
Description: * To limit undesirable oral ingestion, the appropriate dose for the patient will be determined with the help of the dosing guide.~* The varnish will be mixed with the brush to avoid separation of the material during storage~* However, to guarantee the best results suction will be used during application of the varnish.~* A thin uniform layer of the varnish will be applied on the lesion surface by using the supplied brush~* The applicator brush won't be moved through accumulated saliva to prevent premature setting on the bristles.~* After application the patient will be instructed to close his mouth, avoid rinsing, eating soft diet and avoid hot drinks for 4 hrs.
Study NCT05883150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized Midazolam
Description: All the drug solutions will be freshly prepared on the day of sedation session. Depending on the dosage calculated from the weight of each child The sedative drug, the dosage will be diluted with an equal volume by adding distilled water.~The child will be seated in an upright position on the dental chair. Before placing the mask of the nebulizer, the child will be coached into proper breathing pattern
Study NCT05883150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Midazolam
Description: All the drug solutions will be freshly prepared on the day of sedation session. Depending on the dosage calculated from the weight of each child, For children who will receive midazolam using the atomization device attached to a three-ml syringe, the child sitting reclined in knee-to-knee position. Half of the dose will be sprayed in the right nostril and the other half will be sprayed in the left nostril to double the absorptive surface area by short and quick puffs
Study NCT05434689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Iberdomide (Iber, CC-220) is a novel cereblon E3 ligase modulator (CELMoD) in development for treatment of multiple myeloma and other conditions.
Study NCT05434689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Anti-CD 38 monoclonal antibody established in the treatment of multiple myeloma
Study NCT05434689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Corticosteroid active against multiple myeloma in combination with other agents
Study NCT05434689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Second generation proteasome inhibitor with activity in multiple myeloma
Study NCT06157944 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GPT-4
Description: OpenAI's GPT-4 large language model with chat interface.
Study NCT05127889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: curodont
Description: * To limit undesirable oral ingestion, the appropriate dose for the patient will be determined with the help of the dosing guide.~* The varnish will be mixed with the brush to avoid separation of the material during storage~* However, to guarantee the best results suction will be used during application of the varnish.~* A thin uniform layer of the varnish will be applied on the lesion surface by using the supplied brush~* The applicator brush won't be moved through accumulated saliva to prevent premature setting on the bristles.~* After application the patient will be instructed to close his mouth, avoid rinsing, eating soft diet and avoid hot drinks for 4 hrs.
Study NCT05306301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Ponatinib is a novel, synthetic, orally-active TKI discovered using a computational and structure based drug design approach. Ponatinib was specifically designed to inhibit all clinically relevant variants of BCR-ABL1, including the T315I mutant (15-17). In vitro assays have demonstrated that Ponatinib potently inhibits the kinase enzymatic activity of the T315I ABL kinase domain, as well as that of the native (unmutated) enzyme. In leukemia cell lines expressing these BCR-ABL1 variants, Ponatinib potently inhibited BCR-ABL1 signaling, leading to the reduction of cellular proliferation and induction of apoptosis. Ponatinib also inhibits the proliferation of cell lines expressing other major clinically-observed Imatinib-resistant mutants of BCR-ABL1.
Study NCT05003076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methamphetamine
Description: Participants will be given 20 mg of Methamphetamine.
Study NCT05003076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will be given a placebo capsule that will only contain lactose.
Study NCT03923582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive sexual health curriculum
Description: This is a randomized, controlled, single blinded, trial, stratified by health profession, of the intervention versus waitlist control assessing knowledge, attitude change and skill development. At the end of the intervention as compared with waitlist controls.~The intervention was a 4-day, Afrocentric, comprehensive sexual health curriculum. Tanzanian faculty wrote the curriculum in English and Kiswahili to address the most common sexual health challenges clinicians experience in Tanzania. The 4-day curriculum covers sexual health across the lifespan, LGBT and sexual violence, clinical skills training, ethics and policy writing, and community resources and cultural considerations.
Study NCT04835376 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percussion Palm Cup: Safety and Usability of Newly Designed Products in Infants and Children with Cystic Fibrosis
Description: Patients/guardians/caregivers will be given 3 percussor palm cups to use over the course of 6 days. Each cup will be trialed for 2 days, allowing for equal time dedicated to each.
Study NCT05277662 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cell and molecular diagnostics in accordance with functional test results
Description: Procedure: Anorectal manometry (ARM) Studies are performed in the left lateral position with the hips and knees of the subject flexed. Manometric sensor records circumferential pressure. The base of the rectal balloon attached to the ARM catheter is sited 3-5 cm above the upper border of the anal canal, to prevent the balloon impinging upon the anal canal during inflation. The most distal recording sensor is external to anal verge. If any pain or discomfort is experienced, the probe is immediately withdrawn.~Procedure: Rectal sensory test (RST) The test is also performed in the left lateral position with hips and knees flexed. Studies are conducted with either an integrated balloon on the manometric probe or with a separate system. Balloon capacity is no less than 400 mls and all components are latex-free. Insufflation is always performed with air. For ramp distension, the rate should be between 1 and 5 mL/s, and for phasic distension, inflation rate should be set at 10 mL/s (C1).
Study NCT05176444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Individual music therapy sessions across 12-weeks with people with cognitive impairment/dementia. Music therapy training for care home staff at four time points across 12-weeks.